Biorepository & Tissue Analysis Shared Resource
生物样本库
基本信息
- 批准号:10589897
- 负责人:
- 金额:$ 5.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced Malignant NeoplasmAfrican AmericanAnimal ModelApplications GrantsAreaBiological Specimen BanksBiologyBloodCancer CenterCancer Center Support GrantCancer PatientCellsClinicalClinical DataClinical ResearchClinical TrialsCollaborationsConceptionsConsentCooperative Human Tissue NetworkDNADepartment chairDevelopmentDoctor of PhilosophyEmerging TechnologiesEthnic OriginEvaluationFreezingFundingFutureGoalsHematologic NeoplasmsHistologicHistopathologyHumanImageImmuneInstitutional Review BoardsIslandLaboratoriesLeadershipLinkLipidsMalignant NeoplasmsMedicalMedicineNeurofibromatosesNeurofibromatosis 1OncogenesPathologistPathologyPatientsPatternPlayPolysaccharidesPopulation HeterogeneityPositioning AttributePredispositionPreventionProtein GlycosylationProteinsProtocols documentationPublicationsPublishingRNARegimenResearchResearch PersonnelResearch Project GrantsResearch SupportResource SharingResourcesRoleScienceSeaServicesSignal TransductionSolid NeoplasmSouth CarolinaSpecimenSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStrategic PlanningSystemTechniquesTherapeuticTissue DonorsTissue MicroarrayTissue ModelTissue StainsTissue imagingTissuesTranslational ResearchTumor BiologyTumor TissueUniversitiesWorkanimal tissueanticancer researchautosomebiobankcellular imagingclinical diagnosiscost effectivenessdata acquisitiondata repositorydrug developmentdrug efficacyearly onsetethnic diversityexperimental analysisfallsfollow-uphistological specimenshistological stainshuman tissueimprovedinsightinstrumentationinterestlipidomicsliquid crystal polymermeetingsmolecular imagingmultiplexed imagingnew technologypatient derived xenograft modelpre-clinical researchprogramsprotein expressionracial diversityrepositoryresearch studysugarsymposiumtechnology developmenttumortumor microenvironment
项目摘要
BIOREPOSITORY & TISSUE ANALYSIS SHARED RESOURCE: SUMMARY
The Hollings Cancer Center (HCC) Biorepository & Tissue Analysis (BTA) Shared Resource provides investi-
gators with access to meticulously collected and annotated human specimens as well as advanced human and
animal tissue analyses that require state-of-the-art instrumentation and expertise. The shared resource com-
prises several integrated services such as a biospecimen and data repository; customized and readily availa-
ble tissue microarrays; RNA and DNA extractions; research pathology services, including histologic analysis of
fixed, frozen, and stained tissues; and analysis of experimental results. The BTA partners with the Lipidomics
Shared Resource to introduce novel technologies for spatially profiling and imaging proteins, lipids, and gly-
cans in patient tumor tissues. By linking histopathology to the characterization of lipid, sugar, and protein ex-
pression in tissues of clinical interest, the BTA opens the opportunity for HCC investigators to revolutionize tu-
mor tissue analysis and identify previously unrecognized therapeutic avenues.
Since 2013, the BTA has collected more than 26,500 cancer-associated biospecimens from patients with solid
tumors and hematological malignancies, all of which are annotated and linked to clinical data. A notable fea-
ture of the BTA is its ability to tailor the accrual of specimens to meet specific needs of HCC investigators. Cur-
rently, 25% of BTA tissue donors are African American patients, who are typically underrepresented in biore-
positories and in cancer research. During the current funding period, the BTA supported the research of 49
HCC investigators, resulting in 30 publications and 20 funded grant applications. The BTA has made impactful
contributions to advance cancer research at HCC, including the identification of specimens from underserved
patients with Sea Island ancestry and the use of MALDI imaging to study protein glycosylation patterns in can-
cer. In addition to serving a growing group of HCC investigators, the BTA contributes to major national biore-
pository efforts, including the NCI-funded Patient-Derived Xenograft (PDX) Repository, the NCI-funded Coop-
erative Human Tissue Network, and the DOD-funded multi-center NCORP Racially and Ethnically Diverse
Early Onset Repository. Under the leadership of Steven L. Carroll, MD, PhD, an expert in the autosomal domi-
nant tumor susceptibility syndrome neurofibromatosis type 1, the BTA has become an ethnically rich and di-
verse tumor tissue biorepository that serves as an important scientific resource for HCC investigators inter-
ested in linking basic biology findings to the prevention, clinical diagnosis, and treatment of human cancer.
生物样本库和组织分析共享资源:摘要
霍林斯癌症中心 (HCC) 生物样本库和组织分析 (BTA) 共享资源提供研究
鳄鱼能够接触到精心收集和注释的人类标本以及先进的人类和
需要最先进的仪器和专业知识的动物组织分析。共享资源com-
提供多项综合服务,例如生物样本和数据存储库;定制且易于使用
ble组织微阵列; RNA 和 DNA 提取;研究病理学服务,包括组织学分析
固定、冷冻和染色的组织;并分析实验结果。 BTA 与脂质组学合作
共享资源,介绍蛋白质、脂质和糖的空间分析和成像新技术
罐在患者的肿瘤组织中。通过将组织病理学与脂质、糖和蛋白质的表征联系起来
BTA 为 HCC 研究人员彻底改变研究提供了机会
mor 组织分析并确定以前未被识别的治疗途径。
自 2013 年以来,BTA 已从患有实体瘤的患者身上收集了超过 26,500 个与癌症相关的生物样本。
肿瘤和血液恶性肿瘤,所有这些都带有注释并与临床数据相关联。一个值得注意的特点是
BTA 的真正优势在于其能够定制样本的采集以满足 HCC 研究人员的特定需求。当前-
目前,25% 的 BTA 组织捐献者是非裔美国患者,他们在生物重组中的代表性通常不足。
实验室和癌症研究。在当前资助期内,BTA 支持了 49 项研究
HCC 研究人员发表了 30 篇出版物和 20 份资助申请。 BTA 已产生影响
为推进 HCC 癌症研究做出贡献,包括鉴定来自服务不足的样本
具有海岛血统的患者以及使用 MALDI 成像来研究癌症中的蛋白质糖基化模式
cer。除了为越来越多的 HCC 研究人员提供服务外,BTA 还为主要的国家生物研究做出了贡献。
存储库工作,包括 NCI 资助的患者衍生异种移植物 (PDX) 存储库、NCI 资助的合作社
活跃的人体组织网络,以及国防部资助的多中心 NCORP 种族和民族多样化
早发存储库。在常染色体领域专家 Steven L. Carroll 医学博士、哲学博士的领导下
由于 1 型肿瘤易感综合征神经纤维瘤病,BTA 已成为一个种族丰富且多元化的群体
相反的肿瘤组织生物样本库,为 HCC 研究人员提供了重要的科学资源
致力于将基本生物学发现与人类癌症的预防、临床诊断和治疗联系起来。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN L. CARROLL其他文献
STEVEN L. CARROLL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN L. CARROLL', 18)}}的其他基金
Core: Biorepository and Clinical Trial Office Shared Resource
核心:生物样本库和临床试验办公室共享资源
- 批准号:
10911643 - 财政年份:2023
- 资助金额:
$ 5.95万 - 项目类别:
Therapeutic Targeting of Receptor Tyrosine Kinase Hierarchies in Schwann Cell Neoplasms
雪旺细胞肿瘤中受体酪氨酸激酶层次结构的治疗靶向
- 批准号:
10436971 - 财政年份:2020
- 资助金额:
$ 5.95万 - 项目类别:
Therapeutic Targeting of Receptor Tyrosine Kinase Hierarchies in Schwann Cell Neoplasms
雪旺细胞肿瘤中受体酪氨酸激酶层次结构的治疗靶向
- 批准号:
10249969 - 财政年份:2020
- 资助金额:
$ 5.95万 - 项目类别:
Therapeutic Targeting of Receptor Tyrosine Kinase Hierarchies in Schwann Cell Neoplasms - Supplement for Diversity
雪旺细胞肿瘤中受体酪氨酸激酶层次结构的治疗靶向 - 多样性补充
- 批准号:
10527086 - 财政年份:2020
- 资助金额:
$ 5.95万 - 项目类别:
Therapeutic Targeting of Receptor Tyrosine Kinase Hierarchies in Schwann Cell Neoplasms
雪旺细胞肿瘤中受体酪氨酸激酶层次结构的治疗靶向
- 批准号:
10629381 - 财政年份:2020
- 资助金额:
$ 5.95万 - 项目类别:
Therapeutic Targeting of Receptor Tyrosine Kinase Hierarchies in Schwann Cell Neoplasms
雪旺细胞肿瘤中受体酪氨酸激酶层次结构的治疗靶向
- 批准号:
10832284 - 财政年份:2020
- 资助金额:
$ 5.95万 - 项目类别:
Core: Biorepository and Clinical Trial Office Shared Resource
核心:生物样本库和临床试验办公室共享资源
- 批准号:
10246909 - 财政年份:2017
- 资助金额:
$ 5.95万 - 项目类别:
Novel Treatment of NF-1 Associated Malignant Peripheral Nerve Sheath Tumors
NF-1 相关恶性周围神经鞘瘤的新疗法
- 批准号:
7537237 - 财政年份:2007
- 资助金额:
$ 5.95万 - 项目类别:
Novel Treatment of NF-1 Associated Malignant Peripheral Nerve Sheath Tumors
NF-1 相关恶性周围神经鞘瘤的新疗法
- 批准号:
7382342 - 财政年份:2007
- 资助金额:
$ 5.95万 - 项目类别:
相似海外基金
Project 3: Credentialing CDK 4/6 inhibitors used with radiation as an effective treatment strategy in locally advanced ER+ and TNBC
项目 3:认证 CDK 4/6 抑制剂与放射结合使用作为局部晚期 ER 和 TNBC 的有效治疗策略
- 批准号:
10554474 - 财政年份:2023
- 资助金额:
$ 5.95万 - 项目类别:
A Multilevel intervention to address health disparities in lung cancer screening
解决肺癌筛查健康差异的多层次干预
- 批准号:
10746896 - 财政年份:2023
- 资助金额:
$ 5.95万 - 项目类别:
New Hardware and Software Developments for Improving Prostate Metabolic MR Imaging
用于改善前列腺代谢 MR 成像的新硬件和软件开发
- 批准号:
10680043 - 财政年份:2023
- 资助金额:
$ 5.95万 - 项目类别:
Pilot Trial of a "Divine Intervention" to Improve End-of-Life Cancer Care for Black Patients
改善黑人癌症临终护理的“神圣干预”试点试验
- 批准号:
10747114 - 财政年份:2023
- 资助金额:
$ 5.95万 - 项目类别:
Community to Molecular Approaches in Early Screening and Diagnosis to Promote Equitable Outcomes Through the Continuum of Care in Cancer Among Populations of African Ancestry
社区采用分子方法进行早期筛查和诊断,通过对非洲裔人群癌症的持续护理来促进公平结果
- 批准号:
10754038 - 财政年份:2023
- 资助金额:
$ 5.95万 - 项目类别: